Validation of IRDFF-II library by means of Cf spectral averaged cross sections.

Spectrum-averaged cross sections (SACS) is an important quantity usable in validation of nuclear cross sections. Especially in case of dosimetrical reactions there is a request on precise validation. This paper presents SACS measured in the reference Cf(sf) neutron field for neutron dosimetry reactions to validate recently updated IRDFF-II library intended mainly for neutron metrology applications.

Application of Cf neutron source for precise nuclear data experiments.

Purpose of this paper is to provide extensive information helpful for anyone performing any experiment involving Cf neutron source and aiming for high precision experiments. The paper summarizes basic characteristics and fields of study using Cf neutron source. We show the basic characteristics of our source, precise geometry in MCNP6, isotopic content, distribution of the source in the encapsulation and possible use of encapsulation for Al(n,2n)Al reaction estimation and the way of handling of the Cf neutron source in our laboratory.

Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies.

Background: The established safety profile of the fluoroquinolones has been disrupted in the past decade by the detection of low-frequency but potentially serious adverse events that have led to the license suspension, voluntary withdrawal, or restricted use of specific members of the class. Moxifloxacin is a broad-spectrum, advanced-generation fluoroquinolone that has potent activity against respiratory tract infections in adults in both oral and IV formulations.

Objective: The goal of this article was to provide an overview of the cumulative safety data on both oral and IV moxifloxacin, including data from the most recent clinical trials and postmarketing studies.

Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.

Background: Recently, clinical data has emerged suggesting that the fluoroquinolone, gatifloxacin, can affect glucose homeostosis through an unknown mechanism. In order to explore the potential effects of moxifloxacin on glucose metabolism in humans, a pooled analysis of phase II/III clinical trials and postmarketing studies was performed and compared with results from an investigation in laboratory animals.

Methods: A pooled analysis of 30 (26 controlled, 4 uncontrolled) oral and two intravenous/oral prospective, controlled phase II/III moxifloxacin studies was performed to evaluate the frequency of hyper- and hypoglycaemic episodes and glucose-related adverse events and adverse reactions (i.

An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.

Study Objective: To evaluate costs, clinical consequences, and cost-effectiveness from a German and French health-care system perspective of sequential i.v./po moxifloxacin monotherapy compared to co-amoxiclav with or without clarithromycin (AMC +/- CLA) in patients with community-acquired pneumonia (CAP) who required parenteral treatment.